Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

CAR T-cell therapy outcomes in adolescent and young adult patients with non-Hodgkin lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

LMLindsey MurphyMMMatthew MeiFWF. Lennie Wong

Discussion

Loading...

Member takes

Overview

Retrospective cohort analysis demonstrates comparable survival and favorable toxicity in young adults with NHL receiving CAR T-cell therapy.

Key Points

  • Evaluate CAR T-cell therapy outcomes in adolescents and young adults with non-Hodgkin lymphoma compared to older adults.
  • Retrospective matched cohort analysis of patients treated with CD19-directed CAR T-cell product.
  • Cohort included 49 adolescents/young adults matched 1:6 with 294 non-AYA controls on key factors.
  • Primary outcomes measured were progression-free survival and overall survival using multivariable regression techniques.
  • No significant differences in 2-year progression-free survival between AYAs (37%) and non-AYAs (34%).
  • AYAs had lower odds of any immune effector cell-associated neurotoxicity syndrome (ICANS) and prolonged thrombocytopenia.
  • AYAs were more likely to undergo hematopoietic cell transplantation following CAR T-cell therapy.

Cite This Study

Murphy et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e3a2https://doi.org/10.1182/blood-2025-1013
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of age on outcomes of CAR-T cell therapy in multiple myeloma, DLBCL, and follicular lymphoma: A real-world multi-center propensity-matched analysis2025
  2. 2Age-related differences in clinical outcomes among hospitalized recipients of CAR-T cell therapy: A national readmission database analysis2025
  3. 3The influence of advanced age on outcomes in patients with diffuse large B-cell lymphoma treated with CAR-T therapy.2026
  4. 4Anti‐<scp>CD19</scp> chimeric antigen receptor T‐cell therapy in older patients with relapsed or refractory large B‐cell lymphoma: A multicenter study2024 · 10 citations
  5. 5Chimeric antigen receptor‐T cell therapy shows similar efficacy and toxicity in patients with diffuse large B‐cell lymphoma aged 70 and older compared to younger patients: A multicenter cohort study2024 · 35 citations